Page last updated: 2024-12-05

diphenhydramine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8980
CHEMBL ID1620
CHEBI ID4637
SCHEMBL ID17071
MeSH IDM0006507

Synonyms (494)

Synonym
AC-3449
MLS001148114
REGID_FOR_CID_8980
smr000058353
2-[(diphenylmethyl)oxy]-n,n-dimethylethanamine hydrochloride
diphenhydramine.hcl
sekundal-d
belix
hydramine
2-diphenylmethoxy-n,n-dimethylethylamine hydrochloride
einecs 205-687-2
benocten
benadryl preservative free
valdrene
beta-dimethylaminoethyl benzhydryl ether hydrochloride
vena
wehydryl
resmin
ethanamine, 2-(diphenylmethoxy)-n,n-dimethyl-, hydrochloride
benzehist
sleep-eze-3
ccris 2383
halbmond
silphen
bayer select night time pain relief
tylenol pm tablets/caplets
tylenol cold night time liquid
vicks formula 44
benzhydrol, beta-dimethylaminoethyl ether hydrochloride
ethylamine, 2-(diphenylmethoxy)-n,n-dimethyl-, hydrochloride
n,n-dimethyl-2-(diphenylmethoxy)ethylamine hydrochloride
alpha-hydroxydiphenylmethane-beta-dimethylaminoethyl ether hydrochloride
histacyl
nsc 33299
rohydra
dibenil
sedopretten
beldin
diphenylhydramine hydrochloride
ambenyl
benzhydramine hydrochloride
cathejell
nsc-33299
dimedrol hydrochloride
dimedrol-hydrochloride
dobacen hydrochloride
carphenex
nsc33299
dimethylamine benzhydryl ester hydrochloride
carphenamine
2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride
benadryl hydrochloride
2-(benzhydryloxy)-n,n-dimethylethylamine hydrochloride
diphenhydramine hcl
allergival
prodryl
bendylate
wln: 1n1 & 2oyr & r & gh
diphamine
.alpha.-hydroxydiphenylmethane-.beta.-dimethylaminoethyl ether hydrochloride
component of bena-fedrin
component of caladryl
diphenydramine hydrochloride
felben
sk-diphenhydramine
ethylamine,n-dimethyl-2-(diphenylmethoxy)-, hydrochloride
fenylhist
eldadryl
noctomin
.beta.-dimethylaminoethyl benzhydryl ether hydrochloride
difenhydramine hydrochloride
bena
nci-c56075
benzantin hydrochloride
denydryl
dimedrol
benadril hydrochloride
EU-0100377
diphenhydramine hydrochloride, >=98% (hplc)
PRESTWICK_177
hydrochloride, diphenhydramine
147-24-0
diphenhydramine hydrochloride
C07784
diphenhydramine hydrochloride, analytical standard
MLS000758216
cpd000058353 ,
diphenhydramine hydrochloride (jp17/usp)
benadryl (tn)
D00669
NCGC00093809-03
NCGC00024414-05
NCGC00093809-02
MLS000028428 ,
SPECTRUM1500256
NCGC00093809-04
NCGC00093809-01
NCGC00093809-05
MLS002222180
D 3630
D0423
CHEBI:4637 ,
CHEMBL1620
FT-0652576
HMS1568M11
HMS1920I06
AKOS005287308
antitussive agents
dtxsid4020537 ,
NCGC00259023-01
NCGC00254264-01
dtxcid20537
tox21_300611
tox21_112991
tox21_201472
nsc-756729
pharmakon1600-01500256
nsc756729
MLS001423951
CCG-39755
benadryl allergy
diphenhist
diphenhydramine hydrochloride preservative free
unii-tc2d6jad40
banophen
tc2d6jad40 ,
diphenhydramine hydrochloride [usp:ban:jan]
dipjemhist
asdrin
ethanamine, 2-(diphenylmethoxy)-n,n-dimethyl-, hydrochloride (1:1)
LP00377
diphenhydramine hydrochloride [usp monograph]
diphenhydramine hydrochloride [usp-rs]
diphenhydramine hcl [inci]
diphenhydramine hydrochloride [orange book]
diphenhydramine hydrochloride [mart.]
diphenhydramine hydrochloride [mi]
diphenhydramine hydrochloride [jan]
diphenhydramine hydrochloride [ep monograph]
diphenhydramine hydrochloride [vandf]
diphenhydramine hydrochloride [who-dd]
diphenhydramine hydrochloride [ep impurity]
S1866
diphenhydramine (hydrochloride)
HY-B0303A
NC00060
SCHEMBL17071
tox21_500377
NCGC00261062-01
PCHPORCSPXIHLZ-UHFFFAOYSA-N
2-(benzhydryloxy)-n,n-dimethylethanamine hydrochloride
Q-201003
4-acetoxy-3,5-dimethoxybenzoicacid
2-diphenylmethoxy-n,n-dimethylethanamine hydrochloride
OPERA_ID_152
n-(2-diphenylmethoxyethyl)-n,n-dimethylamine hydrochloride
mfcd00012479
2-benzhydryloxy-n,n-dimethylethanamine;hydrochloride
ethylamine, n,n-dimethyl-2-(diphenylmethoxy)-, hydrochloride
2-(benzhydryloxy)-n,n-dimethylethan-1-amine hydrochloride
diphenhydramine hydrochloride, united states pharmacopeia (usp) reference standard
diphenhydramine hydrochloride, european pharmacopoeia (ep) reference standard
diphenhydramine hydrochloride, pharmaceutical secondary standard; certified reference material
diphenhydramine hydrochloride 1.0 mg/ml in methanol (as free base)
sr-01000003069
SR-01000003069-10
SR-01000003069-2
diphenhydramine hydrochloride, british pharmacopoeia (bp) reference standard
SY010546
[2-(diphenylmethoxy)ethyl]dimethylamine hydrochloride
SW198731-2
8052-21-9
n-(2-diphenylmethoxyethyl)-n,n-dimethylamine hcl
diphenhydramine-d5 hydrochloride
1219795-16-0
diphenhydramine hcl (benadryl)
diphenhydramine hydrochloride,(s)
Q26841258
diphenhydramine hydrochloride 100 microg/ml in acetonitrile
AS-12088
BCP13546
EN300-123051
147-24-0 (hcl)
2-benzhydryloxy-n,n-dimethylethanamine hcl
2-benzhydryloxy-n,n-dimethylethanamine;hydron;chloride
2-(benzhydryloxy)-n,n-dimethylethanaminehydrochloride
difenidramina cloridrato
cloridrato de difenidramina
diphenhydramine-d6hydrochloride
Z2239078678
dye-free allergy
diphenhydramine hydrochloride (ep monograph)
sleep-ez nighttime sleep aid
pharbedryl
diphenhydramine hydrochlorideantihistamine
wal-dryl
rest simply
extra strength first aid anti-itchrite aid pharmacy
kroger allergy relief
diphenhydramine hydrochloride 50mg
dye free wal dryl allergy
bactimicina childrens allergy
after bite outdoor
nmnquil
ez nite sleep aid
wal-dryl allergydye free
benadryl allergy ultratab
diphenhydramine hcl 50mg
good sense sleep time
harris teeter childrens allergy
sleep ii
itch relifcvs
allergylil drug store products
valumeds nighttime sleep aid
diphenhydramine hcl 2%
childrens wal-drylsingle-use allergy
complete allergy medicine
allergyantihistamine
meijer childrens allergy reliefbubblegum flavor
kids-eezeallergy
each reliefequate
allergy relief antihistamine
allergy antihistamine
sleepaid (diphenhydramine hcl)
2-(diphenylmethoxy)-n,n-dimethylethylamine monohydrochloride
allergy relief, 24-7 lift by 7-eleven
dye free allergy
allergy reliefcomplete
discount drugmart nighttime sleep-aid
right remedies allergy relief
nighttime sleepaid
wal-sleep zdiphenhydramine hcl / sleep aid
equaline night time sleep aid
careall diphenhydramine
allergy relief 25 mg
good neighbor pharmacy childrens allergy
a health itch relief gel
equaline allergy
circle k allergyantihistamine
allergy relief diphenhydramine hcl 25 mg antihistamine
dg health allergychildrens
basic care nighttime sleep aid
topcare sleep aidnighttime
benzhydrol beta-dimethylaminoethyl ether hydrochloride
wal dryl allergychildrens
first aid shot therapy allergy relief
diphenhydramine hcl 25mg tablet
allergy, circle k
dye free wal sleep z
gnc pet wellness ultra medicated hypo-allergenic
wal-sleep znighttime
nighttime sleep-aid
meijer nighttime sleep aidnon habit forming
benadryl allergy liqui-gels
wal som nighttime sleep aidnighttime
sound body childrens allergy relief
somnapure
texaclear nighttime sleep-aid
premier value sleep-aid
zzzsleep
diphenhydramine oral liquid
allergy reliefchildrens allergy
diphenhydramine hcl oral solution
up and up nighttime sleep-aid
meijer childrens allergy relief
meijer nighttime sleep-aidberry flavor
caring mill childrens allergy
dg health allergy
good neighbor allergy relief
winco foods childrens allergy reliefdye free
childrens allergy reliefdye free bubble gum
simply sleep
maximum strength sleep aid
family wellness sleep aid
robitussin direct runny nose
rexall sleep aid
select brand extra strength itch stopping
up and up childrens allergy melts
boninefaster-acting
complete allergy relief
sleep aidnight time
good neighbor pharmacy allergy
sleep tabsfor nighttime use
benadrylallergy
the itch eraser
only forsleep
diphenhydramine hci 2%
childrens allergy dye free wal-dryl
nighttime sleep aid maximum strength
adult allergy reliefdye free
diphenhydramine hydrochloride (mart.)
nighttime sleep-aid softgel
kosher meds childrens allergy relief
banophen diphenhydramine hcl
dicopanol
sominex max
sunmark allergy relief
maximum strength adult allergy relief
childrens benadryl dye-free allergy
rite aid nighttime sleep aidnon habit forming
premier value nighttime sleep-aid liquidsleep-aid
sleep-aid, circle k
allergy 36ct, caseys 4good
benadryl ultratabs
wal drylchildrens allergy
quality choice nighttime sleep-aid
allergy reliefantihistamine
firstcare allergy relief diphenhydramine hci, 25 mg antihistamine
rite aid nighttime sleep aid
sleepeze eze melts
childrens allergy relief dye free cherry
meijer nighttime sleep-aid
leader nighttime sleep-aid
benadryl extra strength itch stopping
unisom sleepgels nighttime sleep-aid
sleep-aid chewablesnighttime
drx choice childrens allergy chews
nitetime sleep aid
sleep-aidnighttime
maximum strength nighttime sleep aid
easy care first aid diphenhydramine
only for allergy
help i cant sleep
24/7 life allergy relief
adult allergy relief
childrens benadryl allergy
sleepeze minis
xpect extra strength itch relief
somnitabs
kroger nighttime sleep-aid
preferred plus complete allergy medicine
diphenhydraime hcl
allergy attack relief to go
allergy medicine
dye free childrens diphenhydramine hydrochloride
family wellness allergy
nytol
aller-ben
maximum strength nighttime sleep-aid
unisom sleepminis nighttime sleep-aid
allergysoftgel
allergy relief diphenhydramine hci, 25 mg antihistamine
good sense allergy
diphenhydramine hydrochloride (usp-rs)
medique at home diphen
allergy, lil drug store
diphenhydramine hci
conrx allergy
sleep-aidmaximum strength
ez nite sleepnighttime sleep-aid
cvsmaximum strength itch relief
leader sleep aid
allergycircle k
on the go-dose
diphenhydramine hydrochloride 25mg
benadryl allergy extra strength
cvs pharmacy pre-measured spoon childrensallergy medication
childrens allergy dye free wal dryl
rite aid anti-itch
sleep aid nighttime
childrens dye free allergy
firstcare childrens allergy relief
diphenhydramine hcl 25mg
topcare zzz sleep
complete allergy
dye free childrens allergy relief
wal-som
sleep-aid, lil drug store
dye free allergychildrens
allergy relief caplet
vetadryl 10
nighttime sleep-aidnon-habit forming
betr sleep aid
meijer nighttime sleep aid
childrens allergy dye-free wal dryl
allergy get relief
good sense nighttime sleep aid
zzzquil
zzzquil nightime sleep-aid
jet-asleep double strength night time sleep aid
childrens dye free allergy relief
sleep-aid diphenhydramine hcl
diphenhydramine hcl tablets
diphenhydramine hcl 12.5mg / 5ml
exchange select sleeptime
cvs health nighttime sleep-aid
diphenhydramine hcl tablet
leader allergy
diphenhydramine hcl 25 mg
nightime sleep aid
winco foods childrens allergy relief
wal-dryl allergy
itch stopping
sleepeze
select health allergy reliefcherry
diphenhydramine hcl 12.5mg/5ml
diphenhydramine hcl 12.5mg antihistamine
night time sleep-aid
the itch eraser gel
allergy relief diphenhydramine hcl, 25 mg antihistamine
zzzquilfree of
first aid shot therapy sleep aid
berkley and jensen sleep aid
kroger nighttime sleep aid
after bite xtra
sohmed allergy
betr remedies allergy relief
diphenhydramine hydrochloride 50 mg
sleepeze gelcaps
valumeds allergy relief
calmatrol
ez nite sleepnighttime sleep aid
allergy dyefree
allergy relief diphenhydramine hci 25 mg antihistamine
wal-drylallergy
sleep iinighttime sleep aid
best choice childrens allergy relief
diphenhydramine 12.5mg/5ml
allergy relief dye-free softgel
sleep-aid chewables
itch relief gel
diphenhydramine hydrochloride (usp monograph)
allergy reliefdye free
diphenhydramine hydrochloride (ep impurity)
childrens benadryl chewables
fridababy children allergy relief diphenhydramine hcl 12.5mg per 5ml vial, 15ct
axim allergy
allergy reliefdye-free
discount drugmart allergy relief
tecnu calagel
nighttime sleep aidberry flavor
ez nite sleep
wal som nighttime sleep aid
night time sleep aid
medique diphen
histaprin
leader maximum strength sleep aid
wal dryl
foster and thrive childrens allergy relief
nighttime sleep aidmaximum strength
geri-dryl allergy relief
cvs dye-free childrens allergy
allergy relief diphenhydramine hcl 50 mg
allergiesmy child needs help with
antihistamine allergy
wal sleep z
allergychildrens allergy
diphenhydramine antihistamine
zzzquilnighttime sleep-aid
dormmy-lon
sleep aidmaximum strength
adwe dye-free childrens allergy
best choice itch stopping
geri dryl
kids allergy
caring mill night time sleep aid
children allergy relief dye free cherry
correct dosechildrens allergy relief
m-dryl
vetadryl 30
aphenap
childrens allergydye free
children allergy reliefbubblegum flavor
circle k allergy
benadryl ultra tab
best choice childrens allergy reliefbubblegum flavor
nyt time sleep caps
equate itch relief gel
naramin
diphendydramine hydrochloride
caring mill allergy
premier value nighttime sleep aid softgels
benaldryl
nighttime sleep aidalcohol free
childrens allergy reliefdye-free
childrens allergy reliefdye free
sunmark allergy reliefantihistamine
sleep aidnighttime
premier value nighttime sleep-aid liquid
siladryl allergy medicine
physicianscare allergyantihistamine
circle k nighttime sleep-aid
cvs health childrens allergy relief
unisom sleepmelts nighttime sleep-aid
wal-sleep z
qdryl allergy
dye free wal dryl allergychildrens
diphenhydramine hcl caplet, 25mg
sleep tabs
wal dryl allergy
somnapureclinical strength
allergy relief diphenhydramine hcl
cvs health nighttime sleep aid
diphenhydramine.hcl, 1mg/ml in methanol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" They were given individually to guinea pigs prior to poisoning with 2 x LD50 soman to test their efficacy against organophosphorus-induced convulsions, brain damage, and lethality."( Prevention of soman neurotoxicity by non-opioid antitussives.
Braitman, DJ; Brennecke, LH; Sparenborg, S, 1990
)
0.28
" Foetal and peri- and post-natal toxic effects were observed in rats only at 150 mg/kg/d."( Safety and toxicological profile of the new antitussive levodropropizine.
Bestetti, A; Giuliani, P; Melillo, G; Nunziata, A; Tonon, GC, 1988
)
0.27
" However, at this dose level vadocaine is apparently safe and its antitussive properties seem promising enough for further evaluation."( First human studies on the safety and antitussive activity of vadocaine hydrochloride.
Karttunen, P; Männistö, PT; Tukiainen, H; Uusitupa, M, 1988
)
0.27
" On the basis of these results, a 300 mg dose of vadocaine appears to be safe in man in all respects."( Assessment of the safety margin of vadocaine hydrochloride in man.
Helin, M; Karttunen, P; Silvasti, M; Tukiainen, H; Uusitupa, M, 1988
)
0.27
" Adverse events were observed in two patients on moguisteine, three on codeine 15 mg, and five on codeine 30 mg."( The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough.
Barnabè, R; Berni, F; Clini, V; Pirrelli, M; Pisani Ceretti, A; Robuschi, M; Rossi, M; Sestini, P; Tana, F; Vaghi, A, 1995
)
0.29
" No serious adverse events were reported."( Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases.
Allegra, L; Aversa, C; Cazzola, M; Clini, V; Dal Negro, R; Maiorano, V; Tana, F, 1993
)
0.29
" Tolerability was evaluated by laboratory results, vital signs and any adverse event occurring during the clinical trial, including presence or absence of somnolence."( Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer.
Barni, S; Daffonchio, L; Luporini, G; Marchi, E, 1998
)
0.3
"Noscapine, a phthalideisoquinoline alkaloid derived from opium, has been used as an oral anti-tussive agent and has shown very few toxic effects in animals or humans."( Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses.
Archer, DR; Grossniklaus, HE; Joshi, HC; Kapp, JA; Ke, Y; Ye, K, 2000
)
0.31
"In this study, we have focused our investigation of the facts whether co-administration of a NMDA antagonist dextromethorphan (DM) with morphine during pregnancy and throughout lactation could prevent the adverse effects associated with chronic morphine administration in rat offspring."( Co-administration of dextromethorphan during pregnancy and throughout lactation significantly decreases the adverse effects associated with chronic morphine administration in rat offspring.
Su, CH; Tao, PL; Wu, YH; Yeh, GC, 2001
)
0.31
" However, there have been reports of patients experiencing adverse events with related agents."( Safety of selegiline with cold medications.
Jacob, JE; Sage, JI; Wagner, ML, 2003
)
0.32
" If selegiline is used with these medications, watch for adverse events or replace selegiline with another drug."( Safety of selegiline with cold medications.
Jacob, JE; Sage, JI; Wagner, ML, 2003
)
0.32
"The test drug CORSHE-E is an effective and safe cough syrup that is highly acceptable for patients with cough of short duration."( Clinical validation of efficacy and safety of herbal cough formula: study of herbal cough syrup.
Bhagwat, BK; Bhatt, NS; Chitre, D; Johnson, J; Nesari, T, 2004
)
0.32
" Safety was evaluated by means of an analysis of adverse events."( Open trial to assess aspects of safety and efficacy of a combined herbal cough syrup with ivy and thyme.
Büechi, S; Melzer, J; Ramos, M; Vögelin, R; von Eiff, MM, 2005
)
0.33
" Only one adverse event was reported."( Open trial to assess aspects of safety and efficacy of a combined herbal cough syrup with ivy and thyme.
Büechi, S; Melzer, J; Ramos, M; Vögelin, R; von Eiff, MM, 2005
)
0.33
" Two female patients had temporary, not serious adverse drug reactions (stomache ache, mild nausea)."( [Treatment of acute bronchitis in children and adolescents. Non-interventional postmarketing surveillance study confirms the benefit and safety of a syrup made of extracts from thyme and ivy leaves].
Marzian, O, 2007
)
0.34
"Isoline, a major retronecine-type pyrrolizidine alkaloid (PA) from the Chinese medicinal herb Ligularia duciformis, was suggested to be the most toxic known PA."( In vitro metabolism of isoline, a pyrrolizidine alkaloid from Ligularia duciformis, by rodent liver microsomal esterase and enhanced hepatotoxicity by esterase inhibitors.
Akao, T; Hattori, M; Nakamura, N; Sasahara, M; Takagawa, K; Tang, J; Wang, ZT, 2007
)
0.34
"To describe emergency department visits for adverse drug events from cough and cold medications in children."( Adverse events from cough and cold medications in children.
Budnitz, DS; Cohen, AL; Schaefer, MK; Shehab, N, 2008
)
0.35
"Emergency department visits for adverse drug events attributed to cough and cold medications among children aged <12 years were identified from a nationally representative stratified probability sample of 63 US emergency departments from January 1, 2004, through December 31, 2005."( Adverse events from cough and cold medications in children.
Budnitz, DS; Cohen, AL; Schaefer, MK; Shehab, N, 2008
)
0.35
"Timely national surveillance data can help target education, enforcement, and engineering strategies for reducing adverse events from cough and cold medications among children."( Adverse events from cough and cold medications in children.
Budnitz, DS; Cohen, AL; Schaefer, MK; Shehab, N, 2008
)
0.35
" Adverse effects of these medications and the lack of evidence of their efficacy in children make their use a serious matter."( Toxicity and use of over-the-counter cough and cold medication in the pediatric population.
Montgomery, EJ; Wasserman, GS,
)
0.13
" These medications are being placed under extraordinary scrutiny in the pediatric population due to the lack of conclusive evidence about their therapeutic efficacy and increased reports of associations with serious adverse events and even mortality."( Safety and efficacy of over-the-counter cough and cold medicines for use in children.
Kabadi, S; Vassilev, ZP; Villa, R, 2010
)
0.36
"This review confirms the lack of efficacy of OTC cough and cold products in children and reaffirms that although the overall incidence of related serious adverse events is low, such events continue to occur."( Safety and efficacy of over-the-counter cough and cold medicines for use in children.
Kabadi, S; Vassilev, ZP; Villa, R, 2010
)
0.36
" Secondary end-points were the rate of control of chronic cough at each step of therapy, the duration of treatment required, changes in cough symptom score, health-related quality of life and possible adverse effects."( Efficacy and safety of modified sequential three-step empirical therapy for chronic cough.
Li, X; Liang, S; Liu, B; Lü, H; Qiu, Z; Wang, L; Wang, Y; Wei, W; Yu, L, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The goal of this study was to assess CCM-related adverse events (AEs) among children after the withdrawal."( Adverse events from cough and cold medications after a market withdrawal of products labeled for infants.
Budnitz, DS; Kegler, SR; Schaefer, MK; Shehab, N, 2010
)
0.36
" I also describe the potential safety signals identified by FDA using its Adverse Event Reporting System, and their importance in ensuring the safe use of drugs in the post-marketing phase."( [Topics from "Overseas Drug Safety Information" in the past five years].
Amanuma, K, 2013
)
0.39
" The drug's high safety profile was confirmed by the absence of adverse events that could be reliably related to the study treatment, and by monitoring of laboratory variables."( [Rengalin, a New Efficacious and Safe Antitussive Agent. Results of a Randomized, Comparative, Multicenter Clinical Trial in Patients with Acute Respiratory Tract Infections].
Akopov, AL; Aleksandrova, EB; Il'kovich, MM; Petrov, DV; Trofimov, VI, 2015
)
0.42
"Rengalin is a new efficacious and safe drug indicated for the treatment of URI-induced cough."( [Rengalin, a New Efficacious and Safe Antitussive Agent. Results of a Randomized, Comparative, Multicenter Clinical Trial in Patients with Acute Respiratory Tract Infections].
Akopov, AL; Aleksandrova, EB; Il'kovich, MM; Petrov, DV; Trofimov, VI, 2015
)
0.42
" Moreover, the data on adverse events were collected."( [Efficacy and safety of acute bronchitis treatment in adults--a comparison of Bronchosol® syrup and synthetic preparations with ambroxol. Results of observational study].
Fal, AM; Schönknecht, K, 2015
)
0.42
"Bronchosol® syrup is an efficient, well-tolerated, and safe drug."( [Efficacy and safety of acute bronchitis treatment in adults--a comparison of Bronchosol® syrup and synthetic preparations with ambroxol. Results of observational study].
Fal, AM; Schönknecht, K, 2015
)
0.42
" We sought to characterize adverse events associated with dextromethorphan in children <12 years old from a surveillance program of OTC cough/cold medication exposures."( Adverse events associated with pediatric exposures to dextromethorphan.
Banner, W; Bond, GR; Burnham, RI; Green, JL; Kauffman, RE; Palmer, RB; Paul, IM; Reynolds, KM, 2017
)
0.46
"1716 cases contained ≥1 adverse event deemed at least potentially related to dextromethorphan; 1417 were single product exposures."( Adverse events associated with pediatric exposures to dextromethorphan.
Banner, W; Bond, GR; Burnham, RI; Green, JL; Kauffman, RE; Palmer, RB; Paul, IM; Reynolds, KM, 2017
)
0.46
" Adverse events were predominantly associated with overdose, most commonly affecting the central nervous and autonomic systems."( Adverse events associated with pediatric exposures to dextromethorphan.
Banner, W; Bond, GR; Burnham, RI; Green, JL; Kauffman, RE; Palmer, RB; Paul, IM; Reynolds, KM, 2017
)
0.46
"Cases with adverse events (AEs) after ingestion of at least 1 index CCM ingredient (brompheniramine, chlorpheniramine, dextromethorphan, diphenhydramine, doxylamine, guaifenesin, phenylephrine, and pseudoephedrine) in children <12 years of age were collected from 5 data sources."( Safety Profile of Cough and Cold Medication Use in Pediatrics.
Banner, W; Bond, GR; Dart, RC; Green, JL; Kauffman, RE; Palmer, RB; Paul, IM; Reynolds, KM; Wang, GS, 2017
)
0.46
" The new treatment CofNovex plus (EMA) syrup was safe and well tolerated in patient at given specific age group."( To evaluate the efficacy and safety of CofNovex plus (EMA) syrup.
Adhia, MK; Alam, A; Ali, Z; Daniyal, M; Sarfaraz, B; Sattar, A; Usmanghani, K, 2017
)
0.46
" We characterized adverse events (AEs) in children <12 years old associated with CCMs that include both an opioid and over-the-counter (OTC) ingredient."( Adverse events associated with opioid-containing cough and cold medications in children.
Green, JL; Paul, IM; Reynolds, KM, 2018
)
0.48
" The animals were observed for toxic symptoms and mortality daily for 14 days."( A comparative assessment of acute oral toxicity and traditional pharmacological activities between extracts of Fritillaria cirrhosae Bulbus and Fritillaria pallidiflora Bulbus.
Gaun, TKW; Ming, TW; Wang, S; Xu, Y; Ye, B, 2019
)
0.51
"Initial research following regulatory changes addressing the pediatric safety of cough and cold medications (CCMs) demonstrated decreases in adverse events (AEs)."( Trends in adverse events and related health-care facility utilization from cough and cold medication exposures in children.
Banner, W; Bond, GR; Dart, RC; Green, JL; Kauffman, RE; Palmer, RB; Paul, IM; Rapp-Olsson, M; Reynolds, KM; Wang, GS, 2021
)
0.62
"Hedera helix (English ivy) leaf extract syrup was safe to be used in short term during pregnancy for the fetus."( Safety of English ivy (Hedera helix) leaf extract during pregnancy: retrospective cohort study.
Alameer, R; Alghanim, F; Alkattan, A; Alkhairat, M; Alkhalifah, A; Almaary, M; Alsalameen, E; Radwan, N, 2021
)
0.62
" Individual responses and adverse events should be carefully monitored when codeine is used to treat chronic cough."( Effectiveness and Safety of Codeine and Levodropropizine in Patients With Chronic Cough.
Kang, SY; Lee, BJ; Lee, SM; Lee, SP, 2022
)
0.72
"This retrospective analysis of data from IQVIA pharmacy drug dispensing, National Poison Data System, National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project, FDA Adverse Event Reporting System, and the medical literature evaluated exposure trends and medication-related AEs with benzonatate."( Benzonatate Exposure Trends and Adverse Events.
Biehl, A; Cheng, C; Goulding, M; Karami, S; Kim, I; Muñoz, M; Pham, T; Tian, F, 2022
)
0.72
" The proportion of cases with serious adverse effects was low."( Benzonatate Exposure Trends and Adverse Events.
Biehl, A; Cheng, C; Goulding, M; Karami, S; Kim, I; Muñoz, M; Pham, T; Tian, F, 2022
)
0.72
" Rational prescribing and improved provider and caregiver awareness of benzonatate toxic effects may reduce risks associated with benzonatate exposure."( Benzonatate Exposure Trends and Adverse Events.
Biehl, A; Cheng, C; Goulding, M; Karami, S; Kim, I; Muñoz, M; Pham, T; Tian, F, 2022
)
0.72
" Our previous study found that concoction with GRR juice provided a detoxifying effect against the major toxic hepatotoxicity induced by RDB, but the principle for the detoxification of the concoction is unknown to date."( Investigation of the principle of concoction by using the processing excipient Glycyrrhiza uralensis Fisch. juice to reduce the main toxicity of Dioscorea bulbifera L. and enhance its main efficacy as expectorant and cough suppressant.
Duan, Y; Gong, M; He, Q; Ji, L; Li, Y; Qin, L; Song, L; Wang, J; Wang, Y; Wu, X; Zhang, T; Zhang, Y, 2024
)
1.44
"The principle of concoction was investigated by using the processing excipient GRR juice to reduce the major toxic hepatotoxicity of RDB, and the efficacy of RDB as an expectorant and cough suppressant was enhanced."( Investigation of the principle of concoction by using the processing excipient Glycyrrhiza uralensis Fisch. juice to reduce the main toxicity of Dioscorea bulbifera L. and enhance its main efficacy as expectorant and cough suppressant.
Duan, Y; Gong, M; He, Q; Ji, L; Li, Y; Qin, L; Song, L; Wang, J; Wang, Y; Wu, X; Zhang, T; Zhang, Y, 2024
)
1.44
" We measured the content of the main toxic compound diosbulbin B (DB) and serum biochemical indicators and performed pathological analysis in liver tissues of mice to determine the best detoxification process of RDB concocted with GRR juice."( Investigation of the principle of concoction by using the processing excipient Glycyrrhiza uralensis Fisch. juice to reduce the main toxicity of Dioscorea bulbifera L. and enhance its main efficacy as expectorant and cough suppressant.
Duan, Y; Gong, M; He, Q; Ji, L; Li, Y; Qin, L; Song, L; Wang, J; Wang, Y; Wu, X; Zhang, T; Zhang, Y, 2024
)
1.44
"Concoction with GRR juice not only effectively reduced the major toxic hepatotoxicity of RDB but also enhanced its main efficacy as an expectorant and cough suppressant, and that the rationale for the detoxification and/or potentiation of RDB was related to the reduction in the content of the main hepatotoxic compound, DB, the introduction of the hepatoprotective active compounds, LQ and GA, in the auxiliary GRR juice, as well as the inhibition of NF-κB/COX-2/Bax signaling-mediated inflammation and apoptosis."( Investigation of the principle of concoction by using the processing excipient Glycyrrhiza uralensis Fisch. juice to reduce the main toxicity of Dioscorea bulbifera L. and enhance its main efficacy as expectorant and cough suppressant.
Duan, Y; Gong, M; He, Q; Ji, L; Li, Y; Qin, L; Song, L; Wang, J; Wang, Y; Wu, X; Zhang, T; Zhang, Y, 2024
)
1.44

Pharmacokinetics

ExcerptReferenceRelevance
" The peak concentrations of vadocaine were achieved at 1 h both after the tablet and the solution and there were no statistically significant differences in serum concentrations or in pharmacokinetic parameters."( The single dose and steady-state pharmacokinetics of a vadocaine tablet in healthy human volunteers.
Hänninen, U; Karttunen, P; Mykkänen, M; Silvasti, M; Tukiainen, H; Välttilä, S, 1989
)
0.28
"2 h) and eliminated slowly with a mean half-life of 50."( Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies.
Bochner, F; Chen, ZR; Somogyi, A, 1988
)
0.27
" Thus, for later moguisteine pharmacokinetic evaluations the investigation of the plasma concentration-time curve and the urinary excretion of the sole racemic M1 through non-stereospecific analytical methods may suffice in most cases."( Stereoselective pharmacokinetics of moguisteine metabolites in healthy subjects.
Bernareggi, A; Carlesi, RM; Castoldi, D; Ceserani, R; Crema, A; Ratti, D; Ratti, E; Renoldi, MI; Tognella, S,
)
0.13
"5 mg/kg in a crossover fashion in a two-sequence pharmacokinetic study with a wash-out period of at least 7 days."( A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers.
Fleckenstein, LL; Ku, YM; Min, DI; Vichiendilokkul, A, 1999
)
0.3
"93), Cmax (7."( Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
Fitzgerald, JF; Grant, EM; Nicolau, DP; Nightingale, C; Quintiliani, R; Zhong, M, 2001
)
0.31
"The terminal half-life of sabeluzole was significantly prolonged in subjects with severe hepatic dysfunction vs healthy subjects (respectively 39."( Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers.
Blin, O; Bouhours, P; Lacarelle, B; Le Moing, JP; Levron, JC; Micallef, J; Nataf, MB; Pageaux, GP, 2001
)
0.31
"To investigate the enantioselective pharmacokinetic process of benproperine in healthy volunteers."( [Enantioselective pharmacokinetics of benproperine in healthy volunteers].
Chen, XY; Du, ZM; Kang, Y; Zhong, DF, 2000
)
0.31
" An analysis of pharmacokinetic parameters for determining the DM metabolic phenotype was conducted."( Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.
Chen, JY; Ho, HO; Lee, YJ; Sheu, MT; Tao, PL; Yeh, GC,
)
0.13
"We examined the pharmacokinetic and pharmacodynamic properties of liquiritin apioside, a main antitussive component of Glycyrrhizae radix (licorice), with regard to its antitussive effect in guinea pigs."( Pharmacokinetic and pharmacodynamic profiles of the antitussive principles of Glycyrrhizae radix (licorice), a main component of the Kampo preparation Bakumondo-to (Mai-men-dong-tang).
Asano, T; Ichiki, H; Iiduka, A; Kamei, J; Kubo, M; Nakamura, R; Saitoh, A, 2005
)
0.33
"The method is shown to be accurate, and suitable for clinical pharmacokinetic study of levodropropizine."( [Determination of levodropropizine and its pharmacokinetics in human plasma using LC/MS/MS].
Guo, SB; Qiu, F; Sun, YX; Zhao, L; Zhao, LM, 2004
)
0.32
" Whereas 6 subjects of each phenotype were adequate to achieve 80% power in showing pharmacokinetic differences, the power required to detect a difference in antitussive response was less than 80% with 500 subjects in each study arm."( Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Dickinson, GL; Lennard, MS; Proctor, NJ; Rezaee, S; Rostami-Hodjegan, A; Tucker, GT, 2007
)
0.34
" The aim of this study was to quantify the effects of the CYP2D6*1, *2, and *41 variants on DM metabolism in vivo and to identify other sources of pharmacokinetic variability."( Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.
Abduljalil, K; Frank, D; Fuhr, U; Gaedigk, A; Jaehde, U; Jetter, A; Kirchheiner, J; Klaassen, T; Tomalik-Scharte, D, 2010
)
0.36
"Codeine is an important opioid anti-tussive agent whose short half-life (2."( Pharmacokinetics of a novel liquid controlled release codeine formulation.
Beubler, E; Dittrich, P; Haltmeyer, K; Roblegg, E; Zimmer, A, 2011
)
0.37
"A sensitive LC-MS-MS method has been successfully applied to pharmacokinetic study of peimine and peiminine in rat plasma after oral administration of Fritillaria thunbergii Miq."( Comparative pharmacokinetic studies of peimine and peiminine in rat plasma by LC-MS-MS after oral administration of Fritillaria thunbergii Miq. and Fritillaria thunbergii Miq. - Glycyrrhiza uralensis Fisch. couple extract.
Chen, L; Liu, H; Liu, L; Yan, Z; Zhang, H; Zhu, W, 2011
)
0.37
" The method was successfully applied to the pharmacokinetic study after oral administration of single-dose and multiple-dose of moguisteine tablets in healthy Chinese subjects."( Determination of the active metabolite of moguisteine in human plasma and urine by LC-ESI-MS method and its application in pharmacokinetic study.
Bu, F; Guo, R; Liu, X; Song, H; Teng, Y; Wang, B; Wei, C; Yuan, G; Zhang, R; Zhao, W, 2012
)
0.38
" Additionally, there are no published reports of population pharmacokinetic analyses for hydrocodone."( Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules.
Farr, SJ; Melhem, MR; Robinson, CY; Rubino, CM, 2013
)
0.39
" To determine the clinical effect of GSE on CYP2D6, the pharmacokinetic interaction between GSE and the sensitive CYP2D6 probe dextromethorphan in healthy adult volunteers was examined."( The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers.
Beijnen, JH; Goey, AK; Meijerman, I; Schellens, JH, 2013
)
0.39
"6 software was used to calculate pharmacokinetic parameters, and the accumulative absorption percentage of menthol was calculated by Loo-Riegelman method."( [Study on pharmacokinetics and in vitro/in vivo correlation of menthol in Zhike Chuanbei Pipa dropping pills in rats].
Du, C; Liu, D; Liu, JJ; Wang, JL; Wang, LF; Wang, Y; Yang, B, 2013
)
0.39
" This study determined, for the first time, the basic pharmacokinetic profile of DM and its active metabolite, dextrorphan (DP) in children and adolescents."( Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.
Armogida, M; Guenin, E; Riff, D, 2014
)
0.4
" The terminal half-life (t ½) values were longer in the adolescent group due in part to the single PM subject."( Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.
Armogida, M; Guenin, E; Riff, D, 2014
)
0.4
"This is the first evaluation of the pharmacokinetic characteristics of DM in children and adolescents."( Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.
Armogida, M; Guenin, E; Riff, D, 2014
)
0.4
" Finally, the developed method was successfully applied for the determination of dimemorfan in a pharmacokinetic study using healthy Chinese subjects."( Simple and sensitive LC-MS/MS-based assay for the quantification of dimemorfan in human plasma for use in a pharmacokinetic study.
Chen, J; Guo, C; Hua, Y; Pei, Q; Peng, J; Tan, H; Yang, G; Yang, L; Yuan, H, 2015
)
0.42
" In vivo pharmacokinetic (PK), organ toxicity evaluation of combinations, microsomal stability and in vitro cytochrome P450 (CYP) inhibition effects of Nos, Cap and Pip using human liver microsomes were performed."( Noscapine recirculates enterohepatically and induces self-clearance.
Aneja, R; Gundala, SR; Jadhav, GR; Mukkavilli, R; Reid, MD; Vangala, S; Yang, C, 2015
)
0.42
" In this study, we investigated the pharmacokinetic interaction between Zuojin Pill and the sensitive CYP2D6 probe dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype."( Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.
Jiang, J; Liu, S; Miao, P; Qiu, F; Ye, Y; Zeng, J; Zhao, T; Zhu, L, 2016
)
0.43
" In contrast, no significant change was observed in these pharmacokinetic parameters of the participants with CYP2D6*10/*10 genotype."( Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.
Jiang, J; Liu, S; Miao, P; Qiu, F; Ye, Y; Zeng, J; Zhao, T; Zhu, L, 2016
)
0.43
" A physiologically based pharmacokinetic (PBPK) model can be developed to do simulations based on the large virtual Chinese population and evaluate single-point plasma phenotyping method of CYP2D6."( Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.
Berk, D; Chen, R; Hu, P; Rostami-Hodjegan, A; Shi, J; Wang, H, 2016
)
0.43
"Investigate the pharmacokinetic properties of the antitussive dimemorfan phosphate tablets in healthy male and female Chinese volunteers after single and multiple-dose administration; and to evaluate the food-effect on pharmacokinetics of dimemorfan."( Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers.
Luo, Z; Miao, J; Shen, Y; Wang, Y; Xiang, J; Yu, Q, 2017
)
0.46
" The pharmacodynamic study against cough induced by ammonia water in the mouse model and the cough induced by citric acid in the guinea pig model were performed to optimize the extraction process of the sovereign medicinal Indigo Naturalis and the whole prescription of Children's Qingfei Zhisou Syrup."( [Optimization of extraction process of Children's Qingfei Zhisou Syrup based on pharmacodynamics].
Fu, JH; Guo, H; Hao, W; Jin, L; Liu, JX; Liu, ZX; Meng, S; Xu, SJ; Zhao, JF, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" The potentiation of dihydrocodeine-conditioned place preference was observed by combination with chlorpheniramine (0."( Drug interactions in the reinforcing effects of over-the-counter cough syrups.
Masukawa, Y; Misawa, M; Suzuki, T, 1990
)
0.28
" This case highlights the interplay between pharmacogenetic factors, drug-drug interactions, and dose-related toxicity in a child."( Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.
Carleton, BC; Ciszkowski, C; Gong, IY; Hayden, MR; Hildebrandt, D; Koren, G; Lauwers, AE; Madadi, P; Ross, CJ; Schwarz, UI; Sistonen, J, 2010
)
0.36
" In a clinical trial, a strong drug-drug interaction (DDI) was observed between dextromethorphan (DM, the object or victim drug) and GSK1034702 (the precipitant or perpetrator drug), following single and repeat doses."( Retrospective use of PBPK modelling to understand a clinical drug-drug interaction between dextromethorphan and GSK1034702.
Bloomer, J; Dear, G; Hobbs, MJ, 2017
)
0.46
" This trial will evaluate the effects of propofol combined with small doses of dezocine, oxycodone, sufentanil or fentanyl for gastroscopy."( Effect of propofol combined with opioids on cough reflex suppression in gastroscopy: study protocol for a double-blind randomized controlled trial.
Cao, YZ; Lu, X; Xia, J; Xie, J; Yin, N; Yuan, J, 2017
)
0.46
" The magnitude of drug-drug interaction between dextromethorphan and paroxetine was higher in homozygous than in heterozygous subjects (14."( Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Daali, Y; Desmeules, J; Lenglet, S; Matthey, A; Storelli, F; Thomas, A, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
"A reverse-phase High Performance Liquid Chromatographic (HPLC) method was developed for the analysis of metoprolol in the large number of human plasma samples obtained in in vitro-in vivo correlations (IVIVC) and bioavailability studies of extended release formulations of metoprolol tartrate."( A sensitive assay of metoprolol and its major metabolite alpha-hydroxy metoprolol in human plasma and determination of dextromethorphan and its metabolite dextrorphan in urine with high performance liquid chromatography and fluorometric detection.
Eddington, NE; Leslie, J; Mistry, B, 1998
)
0.3
"A multiple dose bioavailability study with six healthy male human volunteers was conducted."( Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers.
Demirbas, S; Reyderman, L; Stavchansky, S, 1998
)
0.3
"Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine."( Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
Fitzgerald, JF; Grant, EM; Nicolau, DP; Nightingale, C; Quintiliani, R; Zhong, M, 2001
)
0.31
" Pharmacokinetic evaluation in the mouse and rat revealed that oral SB 235375 was well absorbed systemically but did not effectively cross the blood-brain barrier."( Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.
Barone, FC; Bush, B; Foley, JJ; Giardina, GA; Griswold, DE; Grugni, M; Hay, DW; Kilian, D; Kotzer, CJ; Legos, JJ; Lundberg, D; Luttmann, MA; Martin, LD; Potts, W; Raveglia, LF; Sandhu, P; Sarau, HM; Schmidt, DB; Underwood, DC, 2002
)
0.31
" Bioavailability (F) of DM increased significantly with grapefruit and seville orange juice, but only returned to half the baseline value after three days of washout."( The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein.
Di Marco, MP; Ducharme, MP; Edwards, DJ; Wainer, IW, 2002
)
0.31
" Oral bioavailability was 11% as calculated from naive pooled data."( Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs.
Kukanich, B; Papich, MG, 2004
)
0.32
" This method was successfully used to analyze plasma samples in a steady-state bioavailability study of a newly developed sustained-release LDP tablets (SR) using immediate-release tablets (IR) as the reference."( HPLC determination and steady-state bioavailability study of levodropropizine sustained-release tablets in dogs.
Li, T; Xu, X; Yan, L; Zhang, R; Zheng, P, 2006
)
0.33
" A complete cross-over bioavailability study of the optimized formulation of the developed sustained tablets and marketed immediate release tablets was performed on six healthy male volunteers."( Formulation and evaluation of dextromethorphan hydrobromide sustained release tablets.
Krishnaraj, K; Meyyanathan, SN; Muralidaharan, S; Rajan, S; Siddaiah, MK; Suresh, B, 2008
)
0.35
" Despite its nontoxic attributes, significant elimination of the disease has not been achieved, perhaps since the bioavailability of noscapine to tumors saturates at an oral dose of 300 mg/kg body weight."( Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
Abdalla, MO; Aneja, R; Karna, P; Mao, H; Sajja, HK; Turner, T; Yates, C, 2011
)
0.37
" could decrease C(max) and prolong MRT(0-infinity) and t1/2 of peimine remarkly with the bioavailability of peimine remained practically unchanged."( Comparative pharmacokinetic studies of peimine and peiminine in rat plasma by LC-MS-MS after oral administration of Fritillaria thunbergii Miq. and Fritillaria thunbergii Miq. - Glycyrrhiza uralensis Fisch. couple extract.
Chen, L; Liu, H; Liu, L; Yan, Z; Zhang, H; Zhu, W, 2011
)
0.37
" The CR preparation showed significantly decreased values of maximum drug concentration (Cmax) and elimination rate (K) than the reference product (LEVOTUS® SYR) but the similar bioavailability (F = 95."( Design, in vitro release characterization and pharmacokinetics of novel controlled release pellets containing levodropropizine.
Cao, QR; Choi, JS; Cui, JH; Liu, Y; Piao, YN; Yang, M, 2014
)
0.4
" The effect of 1-5% w/v of CP on oral bioavailability of Nos (150 mg/kg) was evaluated in Sprague-Dawley rats."( Epithelial transport of noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption.
Chougule, MB; Jackson, T; Patel, AR; Patlolla, R; Singh, M, 2014
)
0.4
" The current study was conducted to develop a sustained-release tablet for imperialine both to prolong absorption time and to improve the oral bioavailability of the drug."( A (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer)-dispersed sustained-release tablet for imperialine to simultaneously prolong the drug release and improve the oral bioavailability.
Deng, L; Fu, Y; Gong, T; Li, J; Lin, Q; Qu, M; Zhang, Z, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Due to the widespread use of antitussives in the clinic it is necessary to develop efficient analytical methodologies for quality control and also for pharmacokinetic, bioavailability and bioequivalence studies."( Characteristics, Properties and Analytical Methods for Determination of Dropropizine and Levodropropizine: A Review.
Machado, AKMDS; Nemitz, MC; Sangoi, MDS; Todeschini, V, 2021
)
0.62
"IAsp-N-Glc is a potential antitussive agent that is first reported to be isolated from Ginkgo Semen, but the bioavailability and excretion of IAsp-N-Glc are unknown."( The bioavailability and excretion of an antitussive compound IAsp-N-Glc in rats by validated UPLC-MS/MS methods.
Chen, S; Cheng, J; Liu, A; Wang, Q; Wang, Y; Zhang, Q, 2020
)
0.56
" To address the limitation of its poor oral bioavailability and low local concentration in the lung, a naringenin-HPβCD inhalation solution was prepared for pulmonary delivery."( Aerosolization Performance, Antitussive Effect and Local Toxicity of Naringenin-Hydroxypropyl-β-Cyclodextrin Inhalation Solution for Pulmonary Delivery.
Fan, W; Guan, M; Shi, R; Su, W; Zeng, X; Zheng, Y, 2021
)
0.62
" However, the clinical therapeutic effect of NRG is limited by its low bioavailability due to poor solubility."( Preparation of Naringenin Nanosuspension and Its Antitussive and Expectorant Effects.
Dong, Z; Guo, Y; Han, M; Meng, Z; Wang, M; Wang, R; Wang, X, 2022
)
0.72
"Naringenin (NRG) is a natural compound with several biological activities; however, its bioavailability is limited owing to poor aqueous solubility."( Optimization of Naringenin Nanoparticles to Improve the Antitussive Effects on Post-Infectious Cough.
Dong, Z; Guo, Y; Han, M; Meng, Z; Wang, M; Wang, R; Wang, X; Yu, B, 2022
)
0.72
"The intestinal microbiota plays a key role in understanding the mechanism of traditional Chinese medicine (TCM), as it could transform the herbal ingredients to metabolites with higher bioavailability and activity comparing to their prototypes."( The activities and mechanisms of intestinal microbiota metabolites of TCM herbal ingredients could be illustrated by a strategy integrating spectrum-effects, network pharmacology, metabolomics and molecular docking analysis: Platycodin D as an example.
He, JW; Huang, HL; Liang, J; Liu, FY; Peng, YM; Qin, Q; Wang, YJ; Zeng, JX; Zhang, SW; Zhang, T; Zhang, XY; Zhong, GY; Zhong, YH, 2023
)
0.91
"The proposed strategy paves a new way for the illustration of the activities and mechanisms of TCM herbal ingredients, which is very important to reconcile the conundrums of TCM herbal ingredients with low oral bioavailability but high activity."( The activities and mechanisms of intestinal microbiota metabolites of TCM herbal ingredients could be illustrated by a strategy integrating spectrum-effects, network pharmacology, metabolomics and molecular docking analysis: Platycodin D as an example.
He, JW; Huang, HL; Liang, J; Liu, FY; Peng, YM; Qin, Q; Wang, YJ; Zeng, JX; Zhang, SW; Zhang, T; Zhang, XY; Zhong, GY; Zhong, YH, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" STC decreased monotonically as dosage increased, and reached a minimum of 3 to 26 with various agonists."( Investigation of narcotics and antitussives using drug discrimination techniques.
Batta, SK; Overton, DA, 1979
)
0.26
" The absorption, tissue distrigution, elimination and biotransformation of the anti-tussive agent Azipranone labelled with 14C have been investigated after oral dosing to rat, dog, baboon and man and parenteral administration to rat and baboon."( The physiological disposition of the anti-tussive agent, 1,2,3,4a,9b-hexahydro-8,9b-dimethyl-4-[3-(4-methylpiperazin-1-yl)propionamido]dibenzofuran-3-one dihydrochloride Azipranone, in man, rat, dog and baboon.
Daniel, JW; James, GW; Rowlands, DA; Taylor, JB, 1978
)
0.26
" In contrast, the morphine dose-response relationship was linear."( The animal pharmacology of buprenorphine, an oripavine analgesic agent.
Cowan, A; Doxey, JC; Harry, EJ, 1977
)
0.26
" The application of the guaiacolsulfonate potassium assay method to commercial dosage forms is reported."( Colorimetric determinations of chlorpheniramine maleate, ephedrine hydrochloride, and guaiacolsulfonate potassium in a cough syrup.
Das Gupta, V; de Lara, AJ, 1975
)
0.25
"One of the principal uses of microencapsulation for pharmaceuticals has been the preparation of sustained-release dosage forms which have been usually presented in the form of a suspension or gel."( Sustained-release dosage form of oxolamine citrate: preparation and release kinetics.
Güneri, T; Kendirci, A; Kirilmaz, L,
)
0.13
" On the other hand, concurrent dosing of dihydrocodeine (2 mg/kg, IP) and a mixture (SC) of methylephedrine (4 mg/kg), caffeine (4 mg/kg) and chlorpheniramine (0."( Drug interactions in the reinforcing effects of over-the-counter cough syrups.
Masukawa, Y; Misawa, M; Suzuki, T, 1990
)
0.28
" Blood and saliva samples and all urine were collected over 168 h after each dosage administration."( Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies.
Bochner, F; Chen, ZR; Somogyi, A, 1988
)
0.27
" For both species the maximum tolerated oral dosage was 24 mg/kg/d."( Safety and toxicological profile of the new antitussive levodropropizine.
Bestetti, A; Giuliani, P; Melillo, G; Nunziata, A; Tonon, GC, 1988
)
0.27
" The side-effects observed were mild in nature and did not require reduction in dosage or withdrawal of the drug in any of the patients."( A comparative randomized double-blind clinical trial of hexapneumine and clistine as antitussive agents.
Chakrabarti, A; Jindal, SK; Malik, SK; Pandhi, P; Sharma, PL, 1987
)
0.27
" Neither was any dose-response relationship noted."( First human studies on the safety and antitussive activity of vadocaine hydrochloride.
Karttunen, P; Männistö, PT; Tukiainen, H; Uusitupa, M, 1988
)
0.27
" The first study involved 90 patients in a double-blind comparative trial of glaucine and codeine: both treatments were administered as a syrup at a dosage of 30 mg 3-times daily for 7 days."( Efficacy and tolerability of glaucine as an antitussive agent.
Criscuolo, D; Dieterich, HA; Gastpar, H, 1984
)
0.27
"0 nm, respectively, have been developed for the specific determination of guaiphenesin in the presence of dextromethorphan, drugs with closely overlapping absorption spectra, in synthetic admixtures and in pharmaceutical dosage forms (tablets and syrups)."( Determination of guaiphenesin in anti-tussive pharmaceutical preparations containing dextromethorphan by first- and second-derivative ultraviolet spectrophotometry.
Hu, TM; Lee, AR, 1994
)
0.29
" After repeated dosing (12-15 days), moguisteine did not induce tolerance in either guinea-pigs or dogs."( Moguisteine: a novel peripheral non-narcotic antitussive drug.
Borghi, A; Ceserani, R; Dalla Rosa, C; Gallico, L; Tognella, S, 1994
)
0.29
" Dose-response curves for noradrenaline were shifted to the right in presence of (S)-boldine."( Selective action of two aporphines at alpha 1-adrenoceptors and potential-operated Ca2+ channels.
Chuliá, S; D'Ocon, MP; Ivorra, MD; Lugnier, C, 1993
)
0.29
" Guinea-pigs were dosed subcutaneously (s."( Central antitussive activity of the NK1 and NK2 tachykinin receptor antagonists, CP-99,994 and SR 48968, in the guinea-pig and cat.
Bolser, DC; DeGennaro, FC; Hey, JA; McLeod, RL; O'Reilly, S, 1997
)
0.3
" The dosage of Zhenkeling was 100 times as clinical dose in acute toxicity test and the dosage was 32, 16, 8 times as clinical dose in long term toxicity test respectively."( [Clinical and experimental studies of zhenkeling oral liquor on treatment infantile cough].
Fang, SQ; Shi, YM; Zhang, YQ, 1996
)
0.29
" It is also devoid of the cardiovascular and behaviour side-effects of theophylline and of effects on diuresis at dosage well above the antitussive dose."( Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]. 2nd communication: investigations on theophylline-like activities.
Arányi, P; Boér, K; Boronkay, E; Gyürky, J; Kapui, Z; Korbonits, D; Lacheretz, F; Mikus, EG; Pascal, M; Révész, J, 1997
)
0.3
"03 mg/kg/infusion), suggesting that DM shifted the dose-response curve for cocaine self-administration to the left."( Dextromethorphan alters the reinforcing effect of cocaine in the rat.
Hong, SY; Jhoo, WK; Kim, HC; Park, BK, 1997
)
0.3
" Levodopa dose-response curves for antiparkinsonian and dyskinetic effects were then compared for each study arm."( Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
Chase, TN; Del Dotto, P; Natté, R; van den Munckhof, P; Verhagen Metman, L, 1998
)
0.3
"An isocratic, reversed-phase liquid chromatographic (LC) method was developed for simultaneous determination of pseudoephedrine hydrochloride (I) and carbinoxamine maleate (II) in a pharmaceutical dosage form."( Determination of pseudoephedrine hydrochloride and carbinoxamine maleate in combination drug formulation by liquid chromatography.
Mansour, AM,
)
0.13
"Intravenous and oral verapamil clearance values were significantly correlated, and cumulative dextromethorphan/3-methoxymorphinan urinary ratios correlated with both plasma AUC(norverapamil)/AUC(verapamil) after oral verapamil dosing and with oral and intravenous verapamil clearance."( In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
Barnas, CR; Gorski, JC; Krecic-Shepard, ME; Schwartz, JB; Slimko, J; Wainer, IW, 1999
)
0.3
" We compared metabolic ratios from six different dextromethorphan phenotyping doses to ascertain whether linearity existed over a dosage range."( Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Bertino, JS; Ellis, RE; Gaedigk, A; Gotschall, R; Kearns, GL; Leeder, JS; Nafziger, AN; Streetman, DS, 1999
)
0.3
"Adverse reactions in infants from maternal drug ingestion depend largely on the amount of milk consumed by the infant, timing of breastfeeding in relation to dosing, dose of the medication, dosing interval, and duration of therapy."( Use of cough and cold preparations during breastfeeding.
Mitchell, JL, 1999
)
0.3
"A high performance liquid chromatography procedure has been developed for the simultaneous determination of guaifenesin pseudoephedrine-dextromethorphan and guaifenesin-pseudoephedrine in commercially available capsule dosage forms and guaifenesin-codeine in a commercial cough syrup dosage form."( HPLC determination of guaifenesin with selected medications on underivatized silica with an aqueous-organic mobile phase.
Stewart, JT; Wilcox, ML, 2000
)
0.31
" A 34 year-old male patient experienced visual hallucinations and severe tremor after dramatically increasing his dosage of oxycodone while on stable amounts of sertraline and cyclosporin."( Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.
Flockhart, DA; Rosebraugh, CJ; Woosley, RL; Yasuda, SU, 2001
)
0.31
" Knowledge of the percolation threshold -- one of the most important concepts in percolation theory -- results in a clear improvement of the solid dosage form design."( Estimation of the percolation thresholds in dextromethorphan hydrobromide matrices.
Caraballo, I; Melgoza, LM; Rabasco, AM; Sandoval, H, 2001
)
0.31
" Three days of validation data are provided along with study sample data from a patient dosed with commercially available Vicks 44."( Increasing bioanalytical throughput using pcSFC-MS/MS: 10 minutes per 96-well plate.
Bolden, RD; Hoke, SH; Morand, KL; Pinkston, JD; Tomlinson, JA; Wehmeyer, KR, 2001
)
0.31
" We explore the toxicities of OTC cough and cold medications, discuss mechanisms of dosing errors, and suggest why physicians should be more vigilant in specifically inquiring about OTCs when evaluating an ill child."( Toxicity of over-the-counter cough and cold medications.
Gunn, VL; Liebelt, EL; Serwint, JR; Taha, SH, 2001
)
0.31
" After the treatment with azelastine, capsaicin-induced cough decreased significantly, and the dose-response curve to capsaicin was shifted to a higher concentration in comparison with the the controls."( Mechanism of the antitussive effect of azelastine in guinea pigs.
Ito, N; Miura, M; Sano, M; Sasaki, M; Shioya, T; Watanabe, A, 2002
)
0.31
" Concurrent dosing of dihydrocodeine and ebastine produced a significant place preference."( Effects of second generation of histamine H1 antagonists, cetirizine and ebastine, on the antitussive and rewarding effects of dihydrocodeine in mice.
Kamei, J; Miyata, S; Morita, K; Onodera, K, 2003
)
0.32
" These results confirmed the respiratory safety of levodropropizine 6% drops administered at the recommended dosage either in healthy volunteers or patients with chronic respiratory impairment."( Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment.
Bruschi, C; Crotti, P; Dacosto, E; Daffonchio, L; Fanfulla, F; Novellini, R, 2003
)
0.32
"In this study, the metabolic ratios of dextromethorphan to dextrorphan (DM/DX) in plasma were calculated at steady state after administering 2 dosage forms (Medicon) and Detusiv) of DM with different release rates."( Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.
Chen, JY; Ho, HO; Lee, YJ; Sheu, MT; Tao, PL; Yeh, GC,
)
0.13
"A high-performance liquid chromatography procedure for the simultaneous determination of aminophylline, methoxyphenamine hydrochloride, noscapine and chlorphenamine maleate in commercially available compound capsule dosage forms has been developed and validated."( HPLC determination of aminophylline, methoxyphenamine hydrochloride, noscapine and chlorphenamine maleate in compound dosage forms with an aqueous-organic mobile phase.
Tang, C; Wu, X; Yin, C, 2003
)
0.32
" The number of coughs is shown to be linearly related to log dose of antibody within a limited range and a dose-response curve is presented."( The effects of drugs upon a graded cough response obtained in sensitized guinea pigs exposed to aerosol of specific antigen.
FLATAKER, L; WINTER, CA, 1955
)
0.23
"We report a case of probable poisoning with codeine phosphate in a 3-month-old infant, which was associated with excessive dosing and concomitant use of antihistamines."( A case of probable codeine poisoning in a young infant after the use of a proprietary cough and cold medicine.
Chan, R; Lee, AC; So, KT, 2004
)
0.32
"The aim of this work was to determine whether a dose-response relationship existed among a group of children administered a single nocturnal dose of DM for cough due to an upper respiratory tract infection."( Dose-response relationship with increasing doses of dextromethorphan for children with cough.
Baker, MS; Berlin, CM; Paul, IM; Shaffer, ML; Sturgis, SA; Yoder, KE, 2004
)
0.32
"A stability indicating high performance liquid chromatography procedure has been developed for the simultaneous determination of guaifenesin (GUA), methyl p-hydroxybenzoate (MHB) and propyl p-hydroxybenzoate (PHB) in a commercial cough syrup dosage form."( Simultaneous, stability indicating, HPLC-DAD determination of guaifenesin and methyl and propyl-parabens in cough syrup.
Allegrone, G; Del Grosso, E; Grosa, G; Russo, R, 2006
)
0.33
" Food and Drug Administration (FDA)-approved dosing recommendations for clinicians prescribing cough and cold medications do not exist for this age group."( Infant deaths associated with cough and cold medications--two states, 2005.
, 2007
)
0.34
" The objective measure of cough reflex sensitivity was the citric acid, dose-response cough challenge."( Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective vs. subjective measures.
Hull, D; Morice, AH; Ramsay, J; Thompson, R; Wright, C, 2008
)
0.35
"A simple and reliable high-performance liquid chromatographic method was developed for the simultaneous determination of mixture of phenylephrine hydrochloride (PHENYL), guaifenesin (GUAIF), and chlorpheniramine maleate (CHLO) either in pure form or in the presence of methylparaben and propylparaben in a commercial cough syrup dosage form."( Simultaneous determination of phenylephrine hydrochloride, guaifenesin, and chlorpheniramine maleate in cough syrup by gradient liquid chromatography.
Abbas, SS; Ali, NM; Amer, SM; Shehata, MA,
)
0.13
" The risk of overdose, incorrect dosing and adverse events is increased in young children due to the greater number of colds they acquire each year."( Over-the-counter cough and cold medication use in young children.
Brewer, M; Ryan, T; Small, L,
)
0.13
"Because of the variability of drop size drug dosage, dosage "by drops" is unprecise and may result in accidental overdose."( Drug dosing error with drops: severe clinical course of codeine intoxication in twins.
Auwärter, V; Ferreirós, N; Hentschel, R; Hermanns-Clausen, M; Müller, C; Pahl, A; Superti-Furga, A; Trittler, R; Weinmann, W, 2009
)
0.35
" A dosage could not be assessed in the remaining 15 cases."( Pediatric fatalities associated with over the counter (nonprescription) cough and cold medications.
Banner, W; Bond, GR; Dart, RC; Green, JL; Kauffman, RE; Manoguerra, AS; Palmer, RB; Paul, IM; Rumack, BH; Winston, DC, 2009
)
0.35
" Information on a respective dose-response relationship is not available."( Dose-response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles.
Bittner, N; Lutz, U; Lutz, WK; Strauch, K, 2009
)
0.35
" Common factors that influenced parental decisions included label saying "infant," graphics (eg, infants, teddy bears, droppers), and dosing directions."( Parental misinterpretations of over-the-counter pediatric cough and cold medication labels.
Choi, L; Finkle, J; Franco, V; Johnston, PE; Kumar, D; Lokker, N; Perrin, EM; Rothman, RL; Sanders, L, 2009
)
0.35
" Pharmacists are also concerned that removing dosing guidelines from packaging may not fully deter parental use of such products."( Cough and cold medication use in young children: Pharmacist reaction to changes in Canada.
Evans, C; Taylor, J,
)
0.13
" After cerebral infarction, intravenous dosing of saline had no effect on these parameters."( Ameliorating effects of cloperastine on dysfunction of the urinary bladder caused by cerebral infarction in conscious rats.
Shirasaki, T; Soeda, F; Takahama, K; Yamamoto, G, 2009
)
0.35
" SCH 486757 does not produce tolerance to its antitussive activity after a 5-day BID dosing regimen."( Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.
Austin, TM; Baptista, M; Bolser, DC; Erickson, CH; Fawzi, AB; Fernandez, X; Hey, JA; Ho, GD; Jia, Y; Korfmacher, W; McLeod, RL; Ng, FW; Parra, LE; Smith-Torhan, A; Tulshian, DB; van Heek, M; Varty, GB; Veals, J; Wainhaus, S; Xu, X; Zimmer, JC, 2010
)
0.36
" In this report, we present the first patient who developed cervical dystonia shortly after the first dose of butamirate citrate, and the patient's symptoms improved immediately after a single intramuscular dosage of biperiden."( Acute cervical dystonia after the first dose of butamirate citrate.
Bayram, E; Hiz, S; Karakaya, P; Topcu, Y; Yis, U, 2013
)
0.39
" During the demonstration, 82% (53/65) stated that they would treat with cough or cold medicines, and 72% (38/53) incorrectly dosed the medication they desired to give."( Cold preparation use in young children after FDA warnings: do concerns still exist?
Lanski, SL; Lazarus, SG; Simon, HK; Smith, AS, 2013
)
0.39
" A nonlinear mixed-effects model compared dose-response parameters by disease group and sex."( Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point.
Baverel, PG; Hilton, EC; Smith, JA; Van Der Graaf, PH; Woodcock, A, 2013
)
0.39
" These results suggested that the pharmacokinetics behavior was similar between ZCPDP and menthol herbs with the same dosage in rats, with good in vitro/in vivo correlation."( [Study on pharmacokinetics and in vitro/in vivo correlation of menthol in Zhike Chuanbei Pipa dropping pills in rats].
Du, C; Liu, D; Liu, JJ; Wang, JL; Wang, LF; Wang, Y; Yang, B, 2013
)
0.39
"The formulations were assessed for their total number, type of dosage form, number of constituents in each formulation, their pharmacological group and rationality."( A comprehensive evaluation of rationality of cough and cold medicines available in Indian market.
Desai, P; Desai, S; Patel, S; Shah, R, 2013
)
0.39
" The rationale behind the use of lozenges as the most favoured dosage form for delivery of anti-tussive substances is presented."( Lozenges as delivery system for upper respiratory catarrh medication.
Bansal, M; Gulati, M; Singh, SK, 2014
)
0.4
" Availability, dosing and duration of use of over-the-counter cough medicines vary significantly in different countries."( Over-the-counter (OTC) medications for acute cough in children and adults in community settings.
Fahey, T; Schroeder, K; Smith, SM, 2014
)
0.4
" However, the optimal dose and safety of chronic dosing are not fully known."( Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders.
Cavendish, JZ; Crowe, MS; Lucke-Wold, BP; Matsumoto, RR; Nguyen, L; Thomas, KL, 2016
)
0.43
" The total dosage employed for aclidinium and tiotropium was 4 mg and 200 μg, respectively."( Downregulation of the cough reflex by aclidinium and tiotropium in awake and anesthetized rabbits.
Bongianni, F; Cinelli, E; Iovino, L; Mutolo, D; Pantaleo, T, 2016
)
0.43
" Metabolic response and dosage variability place children at increased risk of experiencing such side effects."( Codeine versus placebo for chronic cough in children.
Chang, AB; Gardiner, SJ; Marchant, JM; Petsky, HL, 2016
)
0.43
" High dosage of DXM can induce euphoria, dissociative effects and even hallucinations."( Protective effect of Lycium Barbarum polysaccharides on dextromethorphan-induced mood impairment and neurogenesis suppression.
Chan, JN; Fung, TK; Lau, BW; Leung, JW; Po, KK; Sánchez-Vidaña, DI; Sin, EL; Siu, AM; So, KF, 2017
)
0.46
" In parts B and C, patients underwent full dose-response cough challenges with capsaicin and citric acid respectively following single doses of randomly assigned GSK2339345 or placebo (4 study days)."( Effects of a novel sodium channel blocker, GSK2339345, in patients with refractory chronic cough
.
Badri, H; Liefaard, L; Marks-Konczalik, J; McGarvey, LPA; Murdoch, RD; Povey, K; Satia, I; Siederer, S; Smith, JA; Warren, F, 2017
)
0.46
" Safety of the dosing schedules was assessed based on physical examination, recording of adverse events, 12-lead electrocardiography, and laboratory tests."( Single- and multiple-dose pharmacokinetics of the peripheral non-narcotic antitussive moguisteine in healthy Chinese volunteers.
Feng, P; Gou, ZP; Wang, Y; Xiang, J; Zheng, L, 2019
)
0.51
" The result of this study provide some valid scientific support for using BFP as a plant substitute of the BFC, but considering the toxicity of BFP is much higher than BFC, we don't recommend long-term oral administration of BFP or exceeding recommended dosage of Chinese Pharmacopoeia 2015."( A comparative assessment of acute oral toxicity and traditional pharmacological activities between extracts of Fritillaria cirrhosae Bulbus and Fritillaria pallidiflora Bulbus.
Gaun, TKW; Ming, TW; Wang, S; Xu, Y; Ye, B, 2019
)
0.51
" The validated methods were applied to the analysis of PEN-citrate in the dosage form and human serum samples where the drug was successfully resolved from the pharmaceutical additives and serum components with recoveries ≥98."( Extraction-free spectrophotometric assay of the antitussive drug pentoxyverine citrate using sulfonephthalein dyes.
Elfeky, SA; Issa, YM; Mohamed, SH, 2019
)
0.51
" It is marketed in a racemic form or its pure enantiomer called levodropropizine and both are available worldwide in various drug dosage formulations such as tablets, sirup and oral solution."( Characteristics, Properties and Analytical Methods for Determination of Dropropizine and Levodropropizine: A Review.
Machado, AKMDS; Nemitz, MC; Sangoi, MDS; Todeschini, V, 2021
)
0.62
" However, unfortunately, the number of studies in each category of cough medications is minimal, and dosing and treatment duration varies significantly among studies."( Cough Remedies for Children and Adolescents: Current and Future Perspectives.
Brambilla, I; Ciprandi, G; Foiadelli, T; Licari, A; Manti, S; Marseglia, GL; Tosca, MA, 2020
)
0.56
"Three simple, sensitive, precise, reproducible and validated spectrophotometric methods have been developed for the quantification of pipazethate HCl as antitussive drug in pure and dosage forms."( Utilization of N-bromosuccinimide for the sensitive spectrophotometric determination of pipazethate HCl as antitussive drug in pure and dosage forms.
Abourehab, MAS; Ellateif, A; Fawzi, SM; Gouda, AA; Shahin, MHK; Sheikh, RE, 2021
)
0.62
"The developed methods were validated in accordance with ICH guidelines and successfully applied to the analysis of pipazethate HCl in dosage forms with good accuracy and precision."( Utilization of N-bromosuccinimide for the sensitive spectrophotometric determination of pipazethate HCl as antitussive drug in pure and dosage forms.
Abourehab, MAS; Ellateif, A; Fawzi, SM; Gouda, AA; Shahin, MHK; Sheikh, RE, 2021
)
0.62
" The antitussive activity was observed at three dosage levels; 5ml, 10ml and 15ml."( Formulation and evaluation of natural antitussive cough syrups.
Abidi, S; Gilani, U; Imam, S; Mahmood, ZA; Salman, S; Tasleem, F; Zehra Rizvi, SR, 2021
)
0.62
" Eligible subjects met entry criteria and qualified by completing a run-in period where coughs were recorded with a cough monitor after they were dosed with sweet syrup."( Objective and self-reported evidence of dextromethorphan antitussive efficacy in children, aged 6-11 years, with acute cough due to the common cold.
Cruz-Rivera, M; Gelotte, CK; Jayawardena, S; Leyva, RA; Meeves, SG; Moreira, SA; Wilson, BL, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Force Factor Somnapure Clinical Strength - Diphenhydramine HCl -- 50 mg - 30 CapletsForce FactorVitamins & SupplementsDiphenhydramine HCl2024-11-29 10:47:42

Roles (8)

RoleDescription
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
antiemeticA drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
anti-allergic agentA drug used to treat allergic reactions.
muscarinic antagonistA drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
antiparkinson drugA drug used in the treatment of Parkinson's disease.
antipruritic drugA drug, usually applied topically, that relieves pruritus (itching).
local anaestheticAny member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
organoammonium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency5.01190.177814.390939.8107AID2147
endonuclease IVEscherichia coliPotency50.11870.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency29.64520.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency26.83250.000221.22318,912.5098AID743036
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency69.00830.001022.650876.6163AID1224838
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency30.74900.000214.376460.0339AID720691
retinoid X nuclear receptor alphaHomo sapiens (human)Potency42.22380.000817.505159.3239AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency64.27730.001530.607315,848.9004AID1224841; AID1224848; AID1224849
pregnane X nuclear receptorHomo sapiens (human)Potency45.14830.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency40.73080.000229.305416,493.5996AID588513; AID743069; AID743075; AID743077; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency20.29340.001024.504861.6448AID588534; AID743212
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
thyroid stimulating hormone receptorHomo sapiens (human)Potency30.63790.001628.015177.1139AID1224843
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency37.94850.057821.109761.2679AID1159526; AID1159528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency3.54810.010039.53711,122.0200AID588545
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency7.07950.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency43.81730.000323.4451159.6830AID743065; AID743067
mitogen-activated protein kinase 1Homo sapiens (human)Potency18.02580.039816.784239.8107AID1454
eyes absent homolog 2 isoform aHomo sapiens (human)Potency22.38721.199814.641950.1187AID488837
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency31.62280.050127.073689.1251AID588590
survival motor neuron protein isoform dHomo sapiens (human)Potency1.12200.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency17.78280.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency37.63390.002319.595674.0614AID651631
Alpha-synucleinHomo sapiens (human)Potency3.54810.56239.398525.1189AID652106
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency0.89131.000010.475628.1838AID1457
TAR DNA-binding protein 43Homo sapiens (human)Potency0.63101.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (211)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (59)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID339504Increase in non-rapid eye movement sleep time in C57BL mouse assessed during first hour of administration at 20 mg/kg, ip2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Hypaphorine, an indole alkaloid from Erythrina velutina, induced sleep on normal mice.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,812)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901134 (40.33)18.7374
1990's367 (13.05)18.2507
2000's573 (20.38)29.6817
2010's594 (21.12)24.3611
2020's144 (5.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.93 (24.57)
Research Supply Index8.10 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index186.76 (26.88)
Search Engine Supply Index3.98 (0.95)

This Compound (53.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials297 (9.88%)5.53%
Reviews359 (11.95%)6.00%
Case Studies225 (7.49%)4.05%
Observational11 (0.37%)0.25%
Other2,113 (70.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]